| Literature DB >> 29929493 |
C Grégoire1, H Nicolas2, I Bragard3, F Delevallez4, I Merckaert4, D Razavi4, D Waltregny5, M-E Faymonville6, A Vanhaudenhuyse6.
Abstract
BACKGROUND: Prostate and breast cancer can have a lot of negative consequences such as fatigue, sleep difficulties and emotional distress, which decrease quality of life. Group interventions showed benefits to emotional distress and fatigue, but most of these studies focus on breast cancer patients. However, it is important to test if an effective intervention for breast cancer patients could also have benefits for prostate cancer patients.Entities:
Keywords: Breast cancer; Group intervention; Hypnosis; Prostate cancer; Self-care
Mesh:
Year: 2018 PMID: 29929493 PMCID: PMC6013950 DOI: 10.1186/s12885-018-4607-z
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Demographic and medical data of the sample
| Breast cancer patients ( | Prostate cancer patients ( | |||||
|---|---|---|---|---|---|---|
| Treatment group ( | Control group |
| Treatment group ( | Control group |
| |
| Patient demographics | ||||||
| Age (years) | ||||||
| Mean (SD) | 54.3 (10) | 52.5 (6.8) | .535 | 64.11 (5.8) | 65.7 (4.4) | .330 |
| Range | 29–72 | 39–65 | 47–73 | 58–75 | ||
| Cultural origin, | ||||||
| Occidental Europe | 66 (97.0) | 0 | NAa | 25 (100) | 21 (100) | NAa |
| Near and Middle East | 1 (1.5) | 0 | 0 | 0 | ||
| African | 1 (1.5) | 0 | 0 | 0 | ||
| Missing data | 0 | 24 (100) | 0 | 0 | ||
| Marital status, | ||||||
| Single | 5 (7.4) | 1 (4.1) | .778 | 1 (4.0) | 0 | .544 |
| Married/living with partner | 52 (76.5) | 18 (75) | 20 (80.0) | 16 (76.2) | ||
| Divorced/separated/widowed | 11 (16.2) | 5 (20.8) | 4 (16.0) | 5 (23.8) | ||
| Missing data | 0 | 0 | 0 | 0 | ||
| Education level, | ||||||
| Elementary school or less | 0 | 3 (12.5) |
| 1 (4.00) | 2 (9.5) | .557 |
| Lower secondary school | 8 (11.8) | 7 (29.2) | 1 (4.00) | 4 (19.0) | ||
| Upper secondary school | 21 (30.9) | 8 (33.3) | 7 (28.00) | 5 (23.8) | ||
| Bachelor’s degree | 6 (8.8) | 4 (16.7) | 3 (12.00) | 1 (4.8) | ||
| Master’s degree | 29 (42.6) | 2 (8.3) | 12 (48.00) | 8 (38.1) | ||
| Post-graduate | 4 (5.9) | 0 | 1 (4.00) | 1 (4.8) | ||
| Missing data | 0 | 0 | 0 | 0 | ||
| Employment status, | ||||||
| Employed part or full time | 9 (13.2) | 8 (33.3) | .080 | 8 (32.00) | 4 (19.0) | .344 |
| Employed, taken time off | 38 (55.9) | 12 (50) | 2 (8.00) | 3 (14.3) | ||
| Not employed | 20 (29.4) | 4 (16.7) | 15 (60.00) | 14 (66.7) | ||
| Missing data | 1 (1.5) | 0 | 0 | 0 | ||
| Patient medical history | ||||||
| Time since diagnosis (months) | ||||||
| Mean (SD) | 7.1 (5.1) | 5.8 (5.0) | .368 | 6.16 (3.52) | 6.00 (4.3) | .894 |
| Range | 1–27 | 0.5–19 | 1–15 | 2–22 | ||
| Cancer stage, | ||||||
| 0 | 1 (1.5) | 3 (12.5) | 0 | 0 | ||
| 1 | 37 (54.4) | 13 (54.2) | 0 | 0 | ||
| 2 | 22 (32.4) | 3 (12.5) |
| 0 | 0 | |
| 3 | 5 (7.4) | 0 | 0 | 0 | ||
| Missing data | 3 (4.4) | 5 (20.8) | 25b | 21b | ||
| Surgery, | ||||||
| Yes | 68 (100) | 23 (95.8) | NAa | 25 (100) | 21 (100) | NAa |
| No | 0 | 0 | 0 | 0 | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Chemotherapy (CT), | ||||||
| CT completed | 27 (39.7) | 7 (29.2) | .727 | 0 | 0 | NAa |
| During CT | 20 (29.4) | 8 (33.3) | 0 | 0 | ||
| No CT | 21 (30.9) | 8 (33.3) | 25 (100) | 21 (100) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Radiation therapy (RT), | ||||||
| RT completed | 30 (44.1) | 6 (25) | .280 | 1 (4.0) | 0 | .354 |
| During RT | 6 (8.8) | 2 (8.3) | 0 | 0 | ||
| Not yet started | 16 (23.5) | 10 (41.7) | 0 | 0 | ||
| No RT | 16 (23.5) | 5 (20.8) | 24 (96.0) | 21 (100) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Hormonal therapy (HT), | ||||||
| During HT | 38 (55.9) | 8 (33.3) | .209 | 2 (8.0) | 1 (4.8) | .658 |
| Not yet started | 23 (33.8) | 11 (45.8) | 0 | 0 | ||
| No HT | 7 (10.3) | 4 (16.7) | 23 (92.0) | 20 (95.2) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
Bold values indicate significant difference (p < .05)
aNA (Not applicable) when missing data impeded the analysis, or when the two groups are exactly equivalent (p = 1)
bAll prostate cancer patients were recruited after their surgery and none had metastases
Evolution of the data after the intervention in each population
| Breast cancer group | ||||||||
| Treatment group (N = 68) | Control group (N = 24) | |||||||
| T0 | T1 | Evolution (T0-T1) | Effect size | T0 | T1 | Evolution (T0-T1) | Effect size | |
| Mean (SD) | Mean (SD) |
| Cohen’s d | Mean (SD) | Mean (SD) |
| Cohen’s d | |
| HADS – Anxiety | 8.76 (4.14) | 6.70 (3.58) |
| 0.66 | 7.17 (2.96) | 7.58 (3.40) | .916 | −0.13 |
| HADS - Depression | 5.02 (3.16) | 3.84 (3.01) |
| 0.47 | 4.13 (3.72) | 4.04 (3.00) | .999 | 0.04 |
| EORTC – Global Health Status | 59.19 (16.23) | 65.40 (15.83) |
| −0.38 | 56.94 (20.21) | 58.33 (19.19) | .980 | −0.07 |
| EORTC – Fatigue | 52.94 (26.05) | 44.77 (21.72) |
| 0.41 | 51.85 (30.68) | 46.30 (25.94) | .537 | 0.27 |
| Insomnia Severity Index | 12.65 (6.50) | 10.60 (6.15) |
| 0.40 | 10.54 (6.73) | 12.00 (5.54) | .618 | −0.20 |
| Prostate cancer group | ||||||||
| Treatment group (N = 25) | Control group (N = 21) | |||||||
| T0 | T1 | Evolution (T0-T1) | Effect size | T0 | T1 | Evolution (T0-T1) | Effect size | |
| Mean (SD) | Mean (SD) |
| Cohen’s d | Mean (SD) | Mean (SD) |
| Cohen’s d | |
| HADS – Anxiety | 6.50 (3.06) | 4.88 (2.98) | .085 | 0.50 | 4.76 (3.59) | 5.71 (3.81) | .545 | −0.30 |
| HADS - Depression | 3.46 (2.47) | 3.44 (2.89) | .992 | 0.01 | 4.19 (3.28) | 5.05 (4.85) | .516 | −0.29 |
| EORTC – Global Health Status | 67.67 (14.30) | 69.33 (15.54) | .969 | −0.15 | 64.29 (20.94) | 65.48 (25.45) | .983 | −0.07 |
| EORTC – Fatigue | 32.44 (12.39) | 34.22 (16.01) | .876 | −0.11 | 32.27 (27.87) | 29.63 (29.47) | .908 | 0.14 |
| Insomnia Severity Index | 8.04 (5.98) | 6.92 (5.87) | .704 | 0.23 | 6.95 (5.13) | 5.86 (4.29) | .688 | 0.28 |
Bold values indicate significant effects
Baseline differences between breast and prostate cancer patients (Treatment groups only)
| Breast cancer ( | Prostate cancer ( | Baseline comparison ( | |
|---|---|---|---|
| Patients’ demographics | |||
| Age (years) | |||
| Mean (SD) | 54.3 (10) | 64.11 (5.8) |
|
| Range | 29–72 | 47–73 | |
| Cultural origin, | |||
| Occidental Europe | 66 (97.0) | 25 (100) | .687 |
| Near and Middle East | 1 (1.5) | 0 | |
| African | 1 (1.5) | 0 | |
| Missing data | 0 | 0 | |
| Marital status, | |||
| Single | 5 (7.4) | 1 (4.00) | .879 |
| Married/living with partner | 52 (76.5) | 18 (72.00) | |
| Divorced/separated/widowed | 11 (16.2) | 4 (8.00) | |
| Missing data | 0 | 2 (8.00) | |
| Education level, | |||
| Elementary school or less | 0 | 1 (4.00) | .443 |
| Lower secondary school | 8 (11.76) | 1 (4.00) | |
| Upper secondary school | 21 (30.88) | 7 (28.00) | |
| Bachelor’s degree | 6 (8.82) | 1 (4.00) | |
| Master’s degree | 29 (42.65) | 12 (48.00) | |
| Post-graduate | 4 (5.88) | 1 (4.00) | |
| Missing data | 0 | 2 (8.00) | |
| Employment status, | |||
| Employed part or full time | 9 (13.2) | 8 (32.00) |
|
| Employed, taken time off | 38 (55.9) | 2 (8.00) | |
| Not employed | 20 (29.4) | 15 (60.00) | |
| Missing data | 1 (1.5) | ||
| Patients’ medical history | |||
| Time since diagnosis (months) | |||
| Mean (SD) | 7.1 (5.1) | 6.16 (3.52) | .381 |
| Range | 1–27 | 1–15 | |
| Surgery, | |||
| Yes | 68 (100) | 25 (100) | 1.00 |
| No | 0 | 0 | |
| Missing data | 0 | 0 | |
| Chemotherapy (CT), | |||
| CT completed | 27 (39.7) | 0 |
|
| During CT | 20 (29.4) | 0 | |
| No CT | 21 (30.9) | 25 (100) | |
| Missing data | 0 | 0 | |
| Radiation therapy (RT), | |||
| RT completed | 30 (44.1) | 1 (4.00) |
|
| During RT | 6 (8.8) | 0 | |
| Not yet started | 16 (23.5) | 0 | |
| No RT | 16 (23.5) | 24 (96.00) | |
| Missing data | 0 | 0 | |
| Hormonal therapy (HT), | |||
| During HT | 38 (55.9) | 2 (8.00) |
|
| Not yet started | 23 (33.8) | 0 | |
| No HT | 7 (10.3) | 23 (92.00) | |
| Missing data | 0 | 0 | |
| Patients’ psychological state, | |||
| HADS – Anxiety | 8.76 (4.14) | 6.50 (3.06) |
|
| HADS – Depression | 5.02 (3.16) | 3.46 (2.47) | .075 |
| EORTC – Global Health Status | 59.19 (16.23) | 67.67 (14.30) | .066 |
| EORTC – Fatigue | 52.94 (26.05) | 32.44 (12.39) |
|
| Insomnia Severity Index | 12.65 (6.50) | 8.04 (5.98) |
|
Bold values indicate significant differences between the two groups